Despite higher Candida infection occurrence with IL-17 antagonists, most reported cases were mild or moderate infections, none of them were systemic, and most cases could be resolved with appropriate antifungal treatment without causing trial dropouts (41–45). Here, IL17A is linked to candidiasis.